About

Omixon is a global molecular diagnostics company, headquartered in Budapest, Hungary, with US offices in Cambridge, MA that commercializes disruptive technologies for clinical and research laboratories. Omixon’s flagship product, Holotype HLA, an NGS-based HLA genotyping product that delivers the most accurate high-resolution HLA genotyping available, and is used in more than 50+ hospitals worldwide. Omixon’s research software, HLA Explore analyzes data from any sequencing technology and determines HLA genotypes from Whole Exome/Genome Sequencing experiments. Omixon maintains an active grant-funded research program with a product pipeline focused on pre- and post-transplantation, and HLA genotyping applications beyond transplantation.

In 2009 we just had a roadmap, ideas and plans to develop a global molecular diagnostics company in the field of Next Generation Sequencing. We managed to find out our direction and have become a significant player on the HLA-typing market.

Our Executive Team have spent more than a decade leading Software, NGS and genomics companies. Our Research and Development Team have a mixture of experience in all aspects of molecular diagnostics, with experts in software development, bioinformatics and genomics. Professor Dimitri Monos who serves as Chairman of the Scientific Advisory Board was one of the pioneers of NGS for HLA, and the inventor of the Holotype. Our major collaborators and key opinion leaders in the HLA community have provided the highest level of leadership within the community for several decades and Omixon has evolved into a global molecular diagnostics company that currently focuses on driving the adoption of NGS in the clinic with Holotype HLA, an NGS-based HLA genotyping Assay and Software product.